2020 ACC\/AHA Guidelines & 2021 ESC Guidelines for \u201cValvular Heart Disease\u201d
\nUltra-Short Summary:<\/p>\n
Management of Severe Mitral Regurgitation (MR)
\n1. Primary (degenerative) MR is mainly treated by surgical repair; replacement is used if repair is not possible.
\n2. Transcatheter edge-to-edge repair (TEER) is an option for high-risk surgical patients.
\n3. Surgery is indicated in symptomatic patients or asymptomatic patients with LV dysfunction, atrial fibrillation, or pulmonary hypertension.
\n4. In functional (secondary) MR, first-line treatment is guideline-directed medical therapy (GDMT) for heart failure.
\n5. If symptoms persist despite GDMT, TEER is preferred; surgery is reserved for selected cases.
\n6. Use of Surgery or TEER in Functional MR:
\n\u2022 Functional (secondary) MR:
\n\u2022 First-line treatment: Guideline-directed medical therapy (GDMT) for heart failure.
\n\u2022 If symptoms persist despite GDMT:
\n\u2022 TEER (e.g., MitraClip) is recommended for selected patients (based on COAPT trial).
\n\u2022 Surgery is considered if the patient undergoes other cardiac surgery (e.g., CABG) or in highly selected cases.<\/p>\n
Key Points: 2020 ACC\/AHA Guidelines & 2021 ESC Guidelines for \u201cValvular Heart Disease\u201d Ultra-Short Summary: Management of Severe Mitral Regurgitation (MR) 1. Primary (degenerative) MR is mainly treated by surgical repair; replacement is used if repair is not possible. 2. Transcatheter edge-to-edge repair (TEER) is an option for high-risk surgical patients. 3. Surgery is indicated in symptomatic […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6684","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6684"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6684\/revisions"}],"predecessor-version":[{"id":6685,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6684\/revisions\/6685"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\u2022 Primary (degenerative) MR: Surgery is the main treatment.
\n\u2022 Secondary (functional) MR: Focus is on medical therapy first, TEER if needed, surgery in specific cases.
\n1-2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease:
\nhttps:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000923<\/a>
\n2-2021 ESC\/EACTS Guidelines for the Management of Valvular Heart Disease:
\nhttps:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Valvular-Heart-Disease-Guidelines<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"